Molecure S.A.

WSE:MOC Stok Raporu

Piyasa değeri: zł165.8m

Molecure Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Molecure is forecast to grow earnings and revenue by 64.7% and 108.5% per annum respectively.

Anahtar bilgiler

64.7%

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi15.4%
Gelir büyüme oranı108.5%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme16 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Kazanç ve Gelir Büyüme Tahminleri

WSE:MOC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (PLN Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20267915N/A471
12/31/202549-36N/A251
12/31/20244-27N/A-251
9/30/20242-31-61-33N/A
6/30/20242-30-67-29N/A
3/31/20242-29-55-16N/A
12/31/20234-28-57-23N/A
9/30/20239-45-53-40N/A
6/30/20238-42-41-34N/A
3/31/20238-39-48-39N/A
12/31/20228-36-44-34N/A
9/30/20222-16-36-8N/A
6/30/20222-16-38-14N/A
3/31/20222-15-37-15N/A
12/31/20211-14-32-13N/A
9/30/2021124636347N/A
6/30/2021124646247N/A
3/31/2021125676756N/A
12/31/2020125686657N/A
9/30/20202-3-31-2N/A
6/30/20202-3-32-2N/A
3/31/20202-4-38-6N/A
12/31/20192-4-42-7N/A
9/30/20192-5-43-4N/A
6/30/20192-5-41-6N/A
3/31/20191-5-36-4N/A
12/31/20181-4-32-5N/A
9/30/20181-4-28-5N/A
6/30/20182-4N/A-2N/A
3/31/20182-2N/A-2N/A
12/31/20171-2N/A-1N/A
9/30/20171-3N/A-5N/A
6/30/20171-3N/A-4N/A
3/31/20171-3N/A-3N/A
12/31/20161-2N/A-1N/A
12/31/20151-1N/A-2N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MOC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.9%).

Kazançlar ve Piyasa: MOC is forecast to become profitable over the next 3 years, which is considered above average market growth.

Yüksek Büyüme Kazançları: MOC is expected to become profitable in the next 3 years.

Gelir ve Pazar: MOC's revenue (108.5% per year) is forecast to grow faster than the Polish market (4.3% per year).

Yüksek Büyüme Geliri: MOC's revenue (108.5% per year) is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if MOC's Return on Equity is forecast to be high in 3 years time

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y